MVIR Medivir AB (publ)
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a potent and selective cathepsin K inhibitor that is in a Phase II trial for the treatment of osteoarthritis, as well as in Phase I trials for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (LCPD); and fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication, which is in Phase I and II trials for the treatment of hepatocellular carcinoma. In addition, the company is developing birinapant, a SMAC-mimetic for the treatment of solid tumors; VBX-1000 (MIC-701), a selective cathepsin K inhibitor for the treatment of canine periodontitis; USP-7, a preclinical research program for the treatment of cancer; and MET-X (MBLI), a preclinical project for the treatment of infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Medivir (STO: MVIR)
›
Medivir (STO: MVIR) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 1.124 SEK on 19 November 2026, up 154.3% over 52 weeks. Its 52-week range is 0.3400 SEK to 2.885 SEK: the price is 61.0% below the high and 230.6% above the low.
Its market capitalisation is 701.58M SEK.
Medivir reports return on equity of -60.8% and revenue down 20.0% year over year.
It holds more cash than debt, a net cash position of 244.10M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 3.950 SEK is 251.4% above the current price. The next earnings report is expected on 18 February 2027.